Today's 3 Most Volatile Biotech Stocks

Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit.

The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided risk. But while the 2% drop in the industry ETF was noteworthy, the move pales in comparison to the losses and gains posted by these three stocks.

Zogenix  and bluebird bio sunk by 12% and 8%, respectively.  And TherapeuticsMD  surged over 30% higher.

In the following slideshow, you'll learn what's behind the massive moves in these three stocks and see if I think any offer an investing angle worth considering. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


The article Today's 3 Most Volatile Biotech Stocks originally appeared on

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends shares of Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story